Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 5/2015

01-05-2015 | Original Paper

Antiretroviral Drug Diversion Links Social Vulnerability to Poor Medication Adherence in Substance Abusing Populations

Authors: Kiyomi Tsuyuki, Hilary L. Surratt

Published in: AIDS and Behavior | Issue 5/2015

Login to get access

Abstract

Antiretroviral (ARV) medication diversion to the illicit market has been documented in South Florida, and linked to sub-optimal adherence in people living with HIV. ARV diversion reflects an unmet need for care in vulnerable populations that have difficulty engaging in consistent HIV care due to competing needs and co-morbidities. This study applies the Gelberg–Andersen behavioral model of health care utilization for vulnerable populations to understand how social vulnerability is linked to ARV diversion and adherence. Cross-sectional data were collected from a targeted sample of vulnerable people living with HIV in South Florida between 2010 and 2012 (n = 503). Structured interviews collected quantitative data on ARV diversion, access and utilization of care, and ARV adherence. Logistic regression was used to estimate the goodness-of-fit of additive models that test domain fit. Linear regression was used to estimate the effects of social vulnerability and ARV diversion on ARV adherence. The best fitting model to predict ARV diversion identifies having a low monthly income and unstable HIV care as salient enabling factors that promote ARV diversion. Importantly, health care need factors did not protect against ARV diversion, evidence that immediate competing needs are prioritized even in the face of poor health for this sample. We also find that ARV diversion provides a link between social vulnerability and sub-optimal ARV adherence, with ARV diversion and domains from the Behavioral Model explaining 25 % of the variation in ARV adherence. Our analyses reveal great need to improve engagement in HIV care for vulnerable populations by strengthening enabling factors (e.g. patient–provider relationship) to improve retention in HIV care and ARV adherence for vulnerable populations.
Literature
1.
Inciardi JA, Surratt HL, Kurtz SP, Burke JJ. The diversion of prescription drugs by health care workers in Cincinnati, Ohio. Subst Use Misuse. 2006;41(2):255–64.CrossRefPubMed
2.
Associated Press. AIDS drugs surface on the black market. New York Times; 1995.
3.
Dorschner J. Activists: HIV care scam uses homeless. Miami Herald. 2005;30:2005.
4.
Flaherty M, Gaul G. Florida Medicaid fraud costs millions, report says. Wash Post. 2003;19:2003.
5.
Glasgow K. The new dealers: they’re poor, black, and HIV-positive. Their product? The AIDS medications intended to cure them. Miami New Times; 1999.
6.
Kurtz SP, Buttram ME, Surratt HL. Vulnerable infected populations and street markets for ARVs: Potential implications for PrEP rollout in the USA. AIDS Care. 2013;26(4):1–5.
7.
Surratt HL, Kurtz SP. A national perspective on the abuse and diversion of prescription drugs. Nova Southeastern University Faculty symposium; Nova Southeastern University; 2013.
8.
Bharara P. Manhattan U.S. Attorney Announces charges against 48 individuals in massive medicaid fraud scheme involving the diversion and trafficking of prescription drugs. Scheme caused losses estimated at more than half-a-billion dollars to medicaid and is believed to be the largest single prescription drug diversion scheme ever charged at one time; 2012.
9.
Surratt HL, Kurtz SP, Cicero TJ, O’Grady C, Levi-Minzi MA. Antiretroviral medication diversion among HIV-positive substance abusers in South Florida. Am J Public Health. 2013;103(6):1026–8.CrossRefPubMedCentralPubMed
10.
Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, et al. Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. J Acquir Immune Defic Syndr. 2005;40(1):301–16.CrossRefPubMed
11.
Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. Aids. 2001;15(9):1181–3 Epub 2001/06/21.CrossRefPubMed
12.
Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.CrossRefPubMed
13.
Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother. 2005;55(4):413–6.CrossRefPubMed
14.
Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of prescription drug diversion among drug-involved club-and street-based populations. Pain Med. 2007;8(2):171–83.CrossRefPubMedCentralPubMed
15.
Uldall KK, Palmer B, Whetten K, Mellins C. Adherence in people living with HIV/AIDS, mental illness, and chemical dependency: a review of the literature. AIDS Care. 2004;16(Suppl. 1):S71–96.CrossRefPubMed
16.
Weaver KE, Llabre MM, Durán RE, Antoni MH, Ironson G, Penedo FJ, et al. A Stress and coping model of medication adherence and viral load in HIV-positive men and women on highly active antiretroviral therapy (HAART). Health Psychol. 2005;34(4):385–92.CrossRef
17.
Tsuyuki K, Surratt HL, Levi-Minzi MA, O’Grady CL, Kurtz SP. The demand for antiretroviral drugs in the illicit marketplace: implications for HIV disease management among vulnerable populations. AIDS Behav. 2014;1–12.
18.
Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 2004;18 Suppl 1(Suppl. 1):S19–25. Epub 2004/04/13.
19.
20.
Sharpe TT, Lee LM, Nakashima AK, Elam-Evans LD, Fleming PL. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Community Health. 2004;29(2):117–27.CrossRefPubMed
21.
Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.CrossRefPubMedCentralPubMed
22.
Tucker JS, Edelen MO, Burnam MA, Sherbourne CD, Kung F-Y, Gifford A. Psychosocial mediators of antiretroviral nonadherence in HIV-positive adults with substance use and mental health problems. Health Psychol. 2004;23(4):363–70.CrossRefPubMed
23.
CDC. HIV surveillance report. 2011 Feb 2013. Report No.
24.
Mizuno Y, Wilkinson J, Santibanez S, Rose CD, Knowlton A, Handley K, et al. Correlates of health care utilization among HIV-seropositive injection drug users. AIDS Care. 2006;18(5):417–25.CrossRefPubMed
25.
Gelberg L, Andersen R, Leake B. The behavioral model for vulnerable populations: application to medical care use and outcomes for homeless people. Health Serv Res. 2000;34(6):1273–302.PubMedCentralPubMed
26.
Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(March):1–10.CrossRefPubMed
27.
Andersen R, Bozzette S, Shapiro M, St. Clair P, Morton S, Crystal S, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Services Research. 2000;35(2):389–16.
28.
Katz MH, Cunningham WE, Fleishman JA, Andersen RM, Kellogg T, Bozzette SA, et al. Effect of case management on unmet needs and utilization of medical care and medications among HIV-Infected persons. Ann Intern Med. 2001;135(8):557–65.CrossRefPubMed
29.
30.
31.
Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS care. 2000;12(3):255–66.CrossRefPubMed
32.
Dennis ML, Titus JC, White MK, Unsicker JI, Hodgkins D. Global appraisal of individual needs—initial (GAIN-I). Bloomington: Chestnut Health Systems; 2002.
33.
Van Servellen G, Carpio F, Lopez M, Garcia-Teague L, Herrera G, Monterrosa F, et al. Program to enhance health literacy and treatment adherence in low-income HIV-infected Latino men and women. Aids Patient Care STDs. 2003;17(11):581–94.CrossRefPubMed
34.
Viswanathan H, Anderson R, Thomas J III. Evaluation of an antiretroviral medication attitude scale and relationships between medication attitudes and medication nonadherence. Aids Patient Care STDs. 2005;19(5):306–16.CrossRefPubMed
35.
Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients with inadequate health literacy. Fam Med. 2004;36(8):588–94.PubMed
36.
37.
Bodenlos JS, Grothe KB, Kendra K, Whitehead D, Copeland AL, Brantley PJ. Attitudes toward HIV health care providers scale: development and validation. AIDS Patient Care STDs. 2004;18(12):714–20.CrossRefPubMed
38.
Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.CrossRefPubMed
39.
Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu V. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8(3):261–70.CrossRefPubMed
40.
Kleeberger CA, Buechner J, Palella F, Detels R, Riddler S, Godfrey R, et al. Changes in adherence to highly active antiretroviral therapy medications in the multicenter AIDS cohort study. AIDS. 2004;18(4):683–8.CrossRefPubMed
41.
Mohammed H, Kieltyka L, Richardson-Alston G, Magnus M, Fawal H, Vermund SH, et al. Adherence to HAART among HIV-infected persons in rural Louisiana. Aids Patient Care STDs. 2004;18(5):289–96.CrossRefPubMed
42.
Peretti-Watel P, Spire B, Schiltz M-A, Bouhnik A-D, Heard I, Lert F, et al. Vulnerability, unsafe sex and non-adherence to HAART: evidence from a large sample of French HIV/AIDS outpatients. Soc Sci Med. 2006;62(10):2420–33.CrossRefPubMed
43.
Gebo KA, Keruly J, Moore RD. Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy. J Gen Intern Med. 2003;18(2):104–11.CrossRefPubMedCentralPubMed
44.
Golin CE, Liu H, Hays RD, Miller LG, Beck CK, Ickovics J, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17(10):756–65.CrossRefPubMedCentralPubMed
45.
Singh N, Berman SM, Swindells S, Justis JC, Mohr JA, Squier C, et al. Adherence of human immunodeficiency virus—infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29(4):824–30.CrossRefPubMed
46.
Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. Aids. 1999;13(1):S61–72.PubMed
47.
Ammassari A, Trotta MP, Murri R, Castelli F, Narciso P, Noto P, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31:S123–7.CrossRefPubMed
48.
Flickinger TE, Saha S, Moore RD, Beach MC. Higher quality communication and relationships are associated with improved patient engagement in HIV care. JAIDS J Acquir Immune Defic Syndr. 2013;63(3):362–6.CrossRef
49.
Johnson MO, Chesney MA, Goldstein RB, Remien RH, Catz S, Gore-Felton C, et al. Positive provider interactions, adherence self-efficacy, and adherence to antiretroviral medications among HIV-infected adults: a mediation model. AIDS Patient Care Stds. 2006;20(4):258–68.CrossRefPubMedCentralPubMed
50.
Bodenlos JS, Grothe KB, Whitehead D, Konkle-Parker DJ, Jones GN, Brantley PJ. Attitudes toward health care providers and appointment attendance in HIV/AIDS patients. J Assoc Nurses AIDS Care. 2007;18(3):65–73.CrossRefPubMed
51.
Kempf M-C, McLeod J, Boehme AK, Walcott MW, Wright L, Seal P, et al. A qualitative study of the barriers and facilitators to retention-in-care among HIV-positive women in the rural southeastern United States: implications for targeted interventions. Aids Patient Care STDs. 2010;24(8):515–20.CrossRefPubMed
52.
Johnson MO, Sevelius JM, Dilworth SE, Saberi P, Neilands TB. Preliminary support for the construct of health care empowerment in the context of treatment for human immunodeficiency virus. Patient Prefer Adher. 2012;6(1):395–404.CrossRef
53.
Mallinson RK, Rajabiun S, Coleman S. The provider role in client engagement in HIV care. AIDS Patient Care Stds. 2007;21(S1):S-77–84.CrossRef
54.
Bakken S, Holzemer WL, Brown M-A, Powell-Cope GM, Turner JG, Inouye J, et al. Relationships between perception of engagement with health care provider and demographic characteristics, health status, and adherence to therapeutic regimen in persons with HIV/AIDS. Aids Patient Care STDs. 2000;14(4):189–97.CrossRefPubMed
55.
Demmer C. Relationship with health care provider and adherence to HIV medications. Psychol Rep. 2003;93(2):494–6.CrossRefPubMed
56.
Roberts KJ. Physician–patient relationships, patient satisfaction, and antiretroviral medication adherence among HIV-infected adults attending a public health clinic. Aids Patient Care STDs. 2002;16(1):43–50.CrossRefPubMed
57.
Hart E, Curtis H, Wilkins E, Johnson M. National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patients. HIV Med. 2007;8(3):186–91.CrossRefPubMed
58.
Yuan Y, L’italien G, Mukherjee J, Iloeje U. Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med. 2006;7(3):156–62.CrossRefPubMed
59.
Conviser R, Pounds M. The role of ancillary services in client-centred systems of care. AIDS Care. 2002;14(S1):119–31.CrossRef
60.
Wilson IB, Kaplan S. Physician-patient communication in HIV disease: the importance of patient, physician, and visit characteristics. JAIDS J Acquir Immune Defic Syndr. 2000;25(5):417–25.CrossRef
61.
Epstein RM, Franks P, Fiscella K, Shields CG, Meldrum SC, Kravitz RL, et al. Measuring patient-centered communication in patient–physician consultations: theoretical and practical issues. Soc Sci Med. 2005;61(7):1516–28.CrossRefPubMed
62.
Levi-Minzi MA, Surratt HL. HIV stigma among substance abusing people living with HIV/AIDS: implications for HIV treatment. AIDS Patient Care Stds. 2014;28(8):1–10.CrossRef
63.
Fong O, Ho C, Fung L, Lee F, Tse W, Yuen C, et al. Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Med. 2003;4(2):133–8.CrossRefPubMed
64.
65.
Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS cohort study. JAIDS J Acquir Immune Defic Syndr. 2001;26(1):82–92.CrossRef
66.
Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. JAIDS J Acquir Immune Defic Syndr. 1998;18(2):117–25.CrossRef
67.
Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med. 1999;14(5):267–73.CrossRefPubMedCentralPubMed
68.
Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, Makhema J, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. JAIDS. 2003;34(3):281–8.PubMed
69.
Lanièce I, Ciss M, Desclaux A, Diop K, Mbodj F, Ndiaye B, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. Aids. 2003;17:S103–8.CrossRefPubMed
70.
Ickovics JR, Meade C. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care. 2002;14(3):309–18.CrossRefPubMed
71.
Moatti J-P, Souteyrand Y. Editorial: HIV/AIDS social and behavioural research: past advances and thoughts about the future. Soc Sci Med. 2000;50(11):1519–32.CrossRefPubMed
Metadata
Title
Antiretroviral Drug Diversion Links Social Vulnerability to Poor Medication Adherence in Substance Abusing Populations
Authors
Kiyomi Tsuyuki
Hilary L. Surratt
Publication date
01-05-2015
Publisher
Springer US
Published in
AIDS and Behavior / Issue 5/2015
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-014-0969-7

Other articles of this Issue 5/2015

AIDS and Behavior 5/2015 Go to the issue

Original Paper

Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials

Original Paper

The Demand for Antiretroviral Drugs in the Illicit Marketplace: Implications for HIV Disease Management Among Vulnerable Populations

Original Paper

Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007–2010

Original Paper

HIV Prevalence and Risk Behaviors Among Female Sex Workers in Botswana: Results from the 2012 HIV/STI Bio-Behavioral Study

Original Paper

Lay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study

Original Paper

Male Partner Influence on Women’s HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of “Understanding”

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits